Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-20
2009-11-03
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C435S252300
Reexamination Certificate
active
07612035
ABSTRACT:
Inhibitors of the MAPK pathway, including MEK-directed proteases and small molecule inhibitors, are cytotoxic to human melanoma cells in vitro and in vivo via apoptotic mechanisms. These compounds are used to kill melanoma cells and to treat subjects with melanoma, either alone or in combination with other therapeutic modalities.
REFERENCES:
patent: 5405941 (1995-04-01), Johnson
patent: 5525625 (1996-06-01), Bridges et al.
patent: 5591631 (1997-01-01), Leppla et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 5958721 (1999-09-01), Marshall et al.
patent: 6214851 (2001-04-01), Duncia et al.
patent: 2323845 (1998-07-01), None
patent: 92/19720 (1992-11-01), None
patent: 94/18332 (1994-08-01), None
patent: 94/23039 (1994-10-01), None
patent: 98/25598 (1998-06-01), None
patent: 99/01426 (1999-01-01), None
patent: 99/50439 (1999-10-01), None
patent: 00/37141 (2000-06-01), None
patent: 00/42002 (2000-07-01), None
patent: 00/42029 (2000-07-01), None
patent: 00/56706 (2000-09-01), None
patent: 00/68199 (2000-11-01), None
patent: 00/68201 (2000-11-01), None
patent: 02/076496 (2002-10-01), None
Hsieh et al, 2007 (British J cancer, 97: 453-457).
Bowie (Science, 1990, 257:1306-1310).
Burgess et al ( J of Cell Bio. 111:2129-2138, 1990).
Lazar et al (Molecular and Cellular Biology, 1988, 8:1247-1252).
Kalechman et al. Int J Cancer, 86: 281-288.
Adjei, Alex A., “The Role of Mitogen-Activated ERK-Kinase Inhibitors in Lung Cancer Therapy,” Translational Medicine, Nov. 2005, pp. 221-223.
Milella, M. et al., “Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects,” Current Pharmaceutical Design, 2005, pp. 2779-2795.
Cappuzzo, Frederico et al., “Emerging drugs for non-small cell lung cancer,” Expert Opinion, 2003, pp. 179-192.
Sebolt-Leopold, Judith S., “MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors,” Current Pharmaceutical Design, 2004, pp. 1907-1914.
Arora, N., Site directed mutagenesis of histidine residues in anthrax toxin lethal factor binding domain reduces toxicity. Molecular and Cellular Biochemistry 177: 7-14 (1997).
Brossier F, et al., Role of Toxin Functional Domains in Anthrax Pathogenesis. Infection and Immunity 68 (No. 4): 1781-1786 (Apr. 2000).
Database Biosis Online Biosciences Information Service, Philadelphia, PA; Oct. 1999; Price, David T. et al: “Activation of extracellular signal-regulated kinase in human prostate cancer” (2 pages).
Database Biosis Online Biosciences Information Service, Philadelphia, PA; Nov. 16, 2000; Bonati, Antonio et al., “Selective Inhibition of MEK1 kinase downmodulates ERK activity and proliferation of AML blasts” (2 pages).
Duesbery N, et al., Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase Journal of Applied Microbiology 87: 289-293 (1999).
Duesbery N, et al., CENP-E is an essential kinetochore motor in maturing oocytes and is masked during Mos- dependent, cell cycle arrest at metaphase II. Proc. Natl. Acad. Sci. 94: 9165-9170 (Aug. 1997).
Dunn F.B., Anthrax as a Cancer Drug? Journal of the National Cancer Institute 93 (22): 1680-1681 (Nov. 21, 2001).
Klimpel K, et al., Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Molecular Microbiology 13 (6): 1093-1100 (1994).
Koo H, et al., Enhanced Sensitivity to 1β-D-Arabinofuranosylcytosine and Topoisomerase II Inhibitors in Tumor Cell Lines Harboring Activated ras Oncogenes. Cancer Research 56: 5211-5216 (Nov. 15, 1996).
Liu S, et al., Targeting of Tumor Cells by Surface Urokinase Plasminogen Activator-dependent Anthrax Toxin. The Journal of Biological Chemistry. 276 (21): 17976-17984 (May 25, 2001).
Menard A, et al., The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors. Biochem J. 320: 687-691 (1996).
Oka H, et al. Constitutive Activation of Mitogen-activated Protein (MAP) Kinase in Human Renal Cell Carcinoma. Cancer Research 55: 4182-4187 (Sep. 15, 1995).
Pannifer A, et al., Crystal structure of the anthrax lethal factor. Nature 414: 229-233 (Nov. 8, 2001).
Pellizzari R, et al., Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNγ-induced release of NO and TNFα. FEBS Letters 462: 199-204 (1999).
Pugsley A., Bacterial toxins deliver the goods. Proc. Natl. Acad. Sci, 93: 8155-8156 (Aug. 1996).
Vitale G, et al., Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J. 352: 739-745 (2000).
Weinstein J, et al., An Information-Intensive Approach to the Molecular Pharamcology of Cancer. Science 275: 343-349 (Jan. 17, 1997).
Duesbery Nicholas S.
Koo Han-Mo
Koo, legal representative Eunmi (Kay)
Vande Woude George F.
Davis Minh-Tam
Helms Larry R.
Price Heneveld Cooper DeWitt & Litton LLP
Van Andel Research Institute
LandOfFree
Inhibition of mitogen-activated protein kinase (MAPK)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of mitogen-activated protein kinase (MAPK)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of mitogen-activated protein kinase (MAPK)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4067700